Enliven Therapeutics (ELVN)
NASDAQ:ELVN
US Market
Holding ELVN?
Track your performance easily

Enliven Therapeutics (ELVN) Income Statement

275 Followers

Enliven Therapeutics Income Statement

Last quarter (Q2 2024), Enliven Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Enliven Therapeutics's net income was $-19.95M. See Enliven Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Jan 23Dec 22Dec 21Dec 20
Total Revenue
-----$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 94.97M$ 83.53M-$ -34.27M$ 51.44M$ 41.70M
Operating Income
$ -94.97M$ -83.53M-$ -34.27M$ -51.44M$ -41.70M
Net Non Operating Interest Income Expense
$ 14.24M$ 11.97M-$ 943.00K$ 233.00K$ 483.00K
Other Income Expense
$ 15.00K$ 22.00K-$ -34.90M$ 175.00K$ -145.00K
Pretax Income
$ -80.75M$ -71.58M-$ 1.58M$ -51.38M$ -41.36M
Tax Provision
$ 232.00K--$ 88.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -80.18M$ -71.58M-$ 1.49M$ -51.38M$ -49.22M
Basic EPS
$ -1.87$ -2.01$ -0.01--$ -3.53
Diluted EPS
$ -1.87$ -2.01$ -0.01--$ -3.53
Basic Average Shares
$ 172.11M$ 35.55M$ 16.91M--$ 13.92M
Diluted Average Shares
$ 172.11M$ 35.55M$ 16.91M--$ 13.92M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 94.97M$ 83.53M-$ -34.27M$ 51.44M$ 41.70M
Net Income From Continuing And Discontinued Operation
$ -80.18M$ -71.58M-$ 1.49M$ -51.38M$ -41.36M
Normalized Income
$ -33.52M----$ -41.36M
Interest Expense
------
EBIT
$ -86.67M$ -83.53M-$ 1.58M$ -51.38M$ -41.70M
EBITDA
$ -86.53M$ -83.23M-$ 2.29M$ -51.13M$ -41.60M
Currency in USD

Enliven Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis